Fourteen months on, no anti-rejection drugs: Sana’s cells keep going
Breakthrough T1D UK reported Sana’s gene-engineered islet cells were still making insulin at 14 months, without anti-rejection drugs.
You can file this under real progress that still does not change your day. In Sana’s early study, one patient still had working, gene-engineered insulin-making cells at 14 months, without any anti-rejection drugs. That last part is the point: today’s islet transplants need those harsh, lifelong drugs, so they are kept for the most severe cases.
- Islet cells are the clusters in the pancreas holding the beta cells that make insulin; in Type 1 the immune system destroys them.
- Islet transplants exist on the NHS but rely on anti-rejection drugs (they dampen the immune system) that carry real risks, so they are rare.
- Sana engineered its cells to be harder to spot, and at 14 months they were still alive and making insulin without those drugs.
- This is a single participant, so it shows the idea can last over time, not that it works for everyone yet.
What 14 months adds to the story
This is the same Sana study NPN has followed before: first the cells survived four weeks, then six months, and now Breakthrough T1D UK reports they were still evading the immune system and making insulin at 14 months. Why does the calendar matter so much? Because a cure has to last. Cells that work for a month but fade within a year would not free anyone from insulin. Each longer time point is a small piece of evidence that the engineering, making the cells less visible to the immune system, is holding up rather than slowly failing. That is genuinely encouraging.
Why this is still years away
One participant is not a trial you can draw firm conclusions from. Researchers will need to repeat this in more people, follow them for longer, and show it is both safe and reliable before anyone talks about routine use. The amount of cells given here was part of an early safety study, too, not a full transplant designed to end insulin injections. So the fair summary is this: a real and important signal that immune-invisible cells can last, sitting inside a process that still has larger trials, regulators and NHS decisions ahead of it. Hope is reasonable. A countdown is not.